Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
- 30 November 2011
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 6 (11), 1962-1963
- https://doi.org/10.1097/jto.0b013e31822eec5e
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Finding ALK-Positive Lung Cancer: What Are We Really Looking for?Journal of Thoracic Oncology, 2011
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer, 2011
- Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR MutationJournal of Thoracic Oncology, 2010
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMolecular Cancer, 2010
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008